Anxiety management non-benzodiazepine drugs; pharmacy compounding lessens the risk of substance abuse and benzodiazepine dependence
- At: 2012 FIP Congress in Amsterdam (the Netherlands)
- Type: Poster
- By: SER, Filip (City Department for Skin and Veneral Diseases, Belgrade, Serbia)
- Co-author(s): Draskovic, J. (Pharmacy Belgrade, Belgrade, Serbia)
Petrovic, B. (Gynecology and Obstetrician University Hospital “Narodni front”, Belgrade, Serbia)
The need to reduce the anxiety is of the utmost importance in everyday dermatologic settings. However benzodiazepine use, despite their proven effectiveness is carrying the potential of habit forming and a difficulty in tapering the dose and terminating the treatment.Adding a low-dose tricycle compound or SSRI is a recommended strategy by clinical.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.